MOTIV BTK Randomized Controlled Trial

NARecruitingINTERVENTIONAL
Enrollment

292

Participants

Timeline

Start Date

June 10, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

March 31, 2029

Conditions
Critical Limb Ischemia
Interventions
DEVICE

MOTIV Sirolimus-Eluting Bioresorbable Scaffold

Participants will receive the MOTIV device

DEVICE

Percutaneous Transluminal Angioplasty (PTA) Device

Participants will receive PTA treatment

Trial Locations (4)

52722

RECRUITING

UnityPoint Health Trinity Bettendorf Hospital, Bettendorf

52803

RECRUITING

Cardiovascular Medicine PC, Davenport

94574

RECRUITING

Adventist Health, St. Helena

04109

RECRUITING

University Leipzig, Leipzig

All Listed Sponsors
lead

REVA Medical, Inc.

INDUSTRY